Disruption of nuclear envelope integrity as a possible initiating event in tauopathies.

ASO CP: Neuroscience CRISPR genetic screen LEM domain proteins microtubule associate protein tau neurodegeneration nuclear envelope integrity nuclear envelope rupture tau aggregation tau phosphorylation tauopathy

Journal

Cell reports
ISSN: 2211-1247
Titre abrégé: Cell Rep
Pays: United States
ID NLM: 101573691

Informations de publication

Date de publication:
23 08 2022
Historique:
received: 08 03 2022
revised: 23 06 2022
accepted: 29 07 2022
entrez: 24 8 2022
pubmed: 25 8 2022
medline: 27 8 2022
Statut: ppublish

Résumé

The microtubule-associated protein tau is an abundant component of neurons of the central nervous system. In Alzheimer's disease and other neurodegenerative tauopathies, tau is found hyperphosphorylated and aggregated in neurofibrillary tangles. To obtain a better understanding of the cellular perturbations that initiate tau pathogenesis, we performed a CRISPR-Cas9 screen for genetic modifiers that enhance tau aggregation. This initial screen yielded three genes, BANF1, ANKLE2, and PPP2CA, whose inactivation promotes the accumulation of tau in a phosphorylated and insoluble form. In a complementary screen, we identified three additional genes, LEMD2, LEMD3, and CHMP7, that, when overexpressed, provide protection against tau aggregation. The proteins encoded by the identified genes are mechanistically linked and recognized for their roles in the maintenance and repair of the nuclear envelope. These results implicate the disruption of nuclear envelope integrity as a possible initiating event in tauopathies and reveal targets for therapeutic intervention.

Identifiants

pubmed: 36001963
pii: S2211-1247(22)01067-1
doi: 10.1016/j.celrep.2022.111249
pii:
doi:

Substances chimiques

CHMP7 protein, human 0
Endosomal Sorting Complexes Required for Transport 0
LEMD2 protein, human 0
Membrane Proteins 0
Nuclear Proteins 0
tau Proteins 0

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

111249

Subventions

Organisme : NCI NIH HHS
ID : P30 CA013330
Pays : United States

Informations de copyright

Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declarations of interest The authors are employees of and shareholders in Regeneron Pharmaceuticals (“Regeneron”). Regeneron has filed patent applications around the described work. The authors declare no competing interests.

Auteurs

Marine Prissette (M)

Regeneron Pharmaceuticals, Tarrytown, NY, USA. Electronic address: marine.prissette@regeneron.com.

Wen Fury (W)

Regeneron Pharmaceuticals, Tarrytown, NY, USA.

Matthew Koss (M)

Regeneron Pharmaceuticals, Tarrytown, NY, USA.

Claudia Racioppi (C)

Regeneron Pharmaceuticals, Tarrytown, NY, USA.

Daria Fedorova (D)

Regeneron Pharmaceuticals, Tarrytown, NY, USA.

Ella Dragileva (E)

Regeneron Pharmaceuticals, Tarrytown, NY, USA.

Georgia Clarke (G)

Regeneron Pharmaceuticals, Tarrytown, NY, USA.

Taylor Pohl (T)

Regeneron Pharmaceuticals, Tarrytown, NY, USA.

John Dugan (J)

Regeneron Pharmaceuticals, Tarrytown, NY, USA.

Diana Ahrens (D)

Regeneron Pharmaceuticals, Tarrytown, NY, USA.

Joyce Chiu (J)

Regeneron Pharmaceuticals, Tarrytown, NY, USA.

Charleen Hunt (C)

Regeneron Pharmaceuticals, Tarrytown, NY, USA.

Chia-Jen Siao (CJ)

Regeneron Pharmaceuticals, Tarrytown, NY, USA.

Tara Young (T)

Regeneron Pharmaceuticals, Tarrytown, NY, USA.

Arijit Bhowmick (A)

Regeneron Pharmaceuticals, Tarrytown, NY, USA.

Vitaliy Rogulin (V)

Regeneron Pharmaceuticals, Tarrytown, NY, USA.

Mathieu Desclaux (M)

Regeneron Pharmaceuticals, Tarrytown, NY, USA.

Eric Y Hayden (EY)

Regeneron Pharmaceuticals, Tarrytown, NY, USA.

Michael Podgorski (M)

Regeneron Pharmaceuticals, Tarrytown, NY, USA.

Min Gao (M)

Regeneron Pharmaceuticals, Tarrytown, NY, USA.

Lynn E Macdonald (LE)

Regeneron Pharmaceuticals, Tarrytown, NY, USA.

David Frendewey (D)

Regeneron Pharmaceuticals, Tarrytown, NY, USA.

George D Yancopoulos (GD)

Regeneron Pharmaceuticals, Tarrytown, NY, USA.

Brian Zambrowicz (B)

Regeneron Pharmaceuticals, Tarrytown, NY, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH